Please Read Our Disclaimer

An Independent Analysis of the Manufacturing and Quality Issues of the BNT162b BioNTech/Pfizer Vaccine (Video)

An Independent Analysis of the Manufacturing and Quality Issues of the BNT162b BioNTech/Pfizer Vaccine (Video)

In an online presentation, Dr. Maria Gutschi provides an overview of her independent investigation into the quality issues with the BNT162B2 BioNTech/Pfizer vaccine that were identified by the European Medicines Agency.

Tags: amino acids, autoimmunity, batches, biodistribution, cationic lipids, clinical trials, codons, COVID-19, efficacy, European Medicines Agency (EMA), gene therapy, impurities, lipid nanoparticles, mRNA, PEGlayted lipid, regulatory agencies, safety, syncytin-1, synthetic, translation, vaccines

Share:

Related Posts

CCCA Letter to Regulatory Colleges regarding Ivermectin for Early Treatment of COVID-19

It’s Time to Breathe Easy – Masking: What the Evidence Shows (updated from original post Nov 2021)

Dr. Nathan Riley Podcast: Protect Pregnancy and Breastfeeding Campaign Overview

Search

Top Categories

WANT TO BECOME A MEMBER?

To learn more about how you can join the Canadian Covid Care Alliance click the link below.

Popular Posts

CCCA Newsletter Special: Facial Coverings

The Effectiveness and Risks of Masking for COVID-19

Protect Pregnancy and Breastfeeding-Do No Harm

CCCA Podcast Ep. 2: Unjustified War on BC’s Health Workers

Critique of Mitchell et al. JAMA Publication on COVID-19 Patients in Canadian Hospitals

Stay Connected

Canadian Covid Care Alliance